HSCS Stock Overview
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Heart Test Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.097 |
| 52 Week High | US$1.32 |
| 52 Week Low | US$0.09 |
| Beta | 0 |
| 1 Month Change | -16.68% |
| 3 Month Change | -29.32% |
| 1 Year Change | -89.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.27% |
Recent News & Updates
Shareholder Returns
| HSCS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.7% | 2.1% | 2.9% |
| 1Y | -89.0% | -1.9% | 22.2% |
Return vs Industry: HSCS underperformed the US Medical Equipment industry which returned -1.9% over the past year.
Return vs Market: HSCS underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| HSCS volatility | |
|---|---|
| HSCS Average Weekly Movement | 15.4% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HSCS's share price has been volatile over the past 3 months.
Volatility Over Time: HSCS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 12 | Andrew Simpson | heartsciences.com |
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor’s offices, urgent care centers, and hospitals.
Heart Test Laboratories, Inc. Fundamentals Summary
| HSCS fundamental statistics | |
|---|---|
| Market cap | US$6.39m |
| Earnings (TTM) | -US$6.39m |
| Revenue (TTM) | US$18.60k |
343.3x
P/S Ratio-1.0x
P/E RatioIs HSCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSCS income statement (TTM) | |
|---|---|
| Revenue | US$18.60k |
| Cost of Revenue | US$6.08k |
| Gross Profit | US$12.52k |
| Other Expenses | US$6.40m |
| Earnings | -US$6.39m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 67.31% |
| Net Profit Margin | -34,362.39% |
| Debt/Equity Ratio | 5.8% |
How did HSCS perform over the long term?
See historical performance and comparison